DecisionView (San Francisco, CA) announced today that its Web-based enrollment application, StudyOptimizer, will now be available as Software-as-a-Service (SAS). In addition to faster deployment, the pay-as-you-go version will deliver a lower cost of ownership, says the company.
"We realized the importance of accelerating the adoption of our solution, so that customers could implement corrective actions in their enrollment processes as quickly as possible," said Jim Scullion, Chief Executive Officer of DecisionView. "With the launch of this new offering, companies can leverage the planning and forecasting capabilities of StudyOptimizer in a shorter time frame, even on a single trial."
The SAS model will be hosted in a SAS70 certified infrastructure and is available now.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
First Patient Dosed in Phase III Trial of Enhertu as First-Line Treatment for Endometrial Cancer
June 10th 2025In combination with rilvegostomig or Keytruda, Enhertu will be evaluated versus chemotherapy in the DESTINY-Endometrial01 study for the treatment of patients with HER2-expressing, mismatch repair proficient primary advanced or recurrent endometrial cancer.